speb/financial-data huggingface dataset:
VET cash_flow (quarterly, 2026-03-31) — Long Term Debt Issuance: 0.00
VET cash_flow (quarterly, 2026-03-31) — Long Term Debt Payments: -16223000.00
VET balance_sheet (quarterly, 2026-03-31) — Long Term Provisions: 1049051000.00
VET cash_flow (quarterly, 2026-03-31) — Net Business Purchase And Sale: -6035000.00
VET cash_flow (quarterly, 2026-03-31) — Net Common Stock Issuance: -4692000.00
VET balance_sheet (quarterly, 2026-03-31) — Net Debt: 1237980000.00
VET cash_flow (quarterly, 2026-03-31) — Net Foreign Currency Exchange Gain Loss: 15267000.00
VET income_statement (quarterly, 2026-03-31) — Net Income: -145538000.00
VET income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: -145538000.00
VET income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: -141206000.00
VET income_statement (quarterly, 2026-03-31) — Net Income Discontinuous Operations: -4332000.00
VET income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: -145538000.00
VET income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: -141206000.00
VET cash_flow (quarterly, 2026-03-31) — Net Income From Continuing Operations: -145538000.00
VET income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: -145538000.00
VET income_statement (quarterly, 2026-03-31) — Net Interest Income: -26697000.00
VET cash_flow (quarterly, 2026-03-31) — Net Issuance Payments Of Debt: -16223000.00
VET cash_flow (quarterly, 2026-03-31) — Net Long Term Debt Issuance: -16223000.00
VET income_statement (quarterly, 2026-03-31) — Net Non Operating Interest Income Expense: -26697000.00
VET cash_flow (quarterly, 2026-03-31) — Net Other Financing Charges: 92000.00
VET cash_flow (quarterly, 2026-03-31) — Net Other Investing Changes: -48158000.00
VET balance_sheet (quarterly, 2026-03-31) — Net PPE: 4882369000.00
VET cash_flow (quarterly, 2026-03-31) — Net PPE Purchase And Sale: -134580000.00
VET balance_sheet (quarterly, 2026-03-31) — Net Tangible Assets: 2044623000.00
VET balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Assets: 113891000.00
VET balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Liabilities: 298819000.00
VET balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Assets: 113891000.00
VET balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Liabilities: 298819000.00
VET income_statement (quarterly, 2026-03-31) — Normalized EBITDA: 101716000.00
VET income_statement (quarterly, 2026-03-31) — Normalized Income: 49204000.00
VET cash_flow (quarterly, 2026-03-31) — Operating Cash Flow: 227398000.00
VET cash_flow (quarterly, 2026-03-31) — Operating Gains Losses: 300915000.00
VET income_statement (quarterly, 2026-03-31) — Operating Income: 101665000.00
VET income_statement (quarterly, 2026-03-31) — Operating Revenue: 519125000.00
VET balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 152599504.00
VET balance_sheet (quarterly, 2026-03-31) — Other Current Liabilities: 243905000.00
VET balance_sheet (quarterly, 2026-03-31) — Other Equity Adjustments: 274905000.00
VET income_statement (quarterly, 2026-03-31) — Other Gand A: 19965000.00
VET income_statement (quarterly, 2026-03-31) — Other Income Expense: -317299000.00
VET cash_flow (quarterly, 2026-03-31) — Other Non Cash Items: 6120000.00
VET income_statement (quarterly, 2026-03-31) — Other Non Operating Income Expenses: 51000.00
VET income_statement (quarterly, 2026-03-31) — Other Operating Expenses: 193850000.00
VET balance_sheet (quarterly, 2026-03-31) — Payables: 465230000.00
VET balance_sheet (quarterly, 2026-03-31) — Payables And Accrued Expenses: 465230000.00
VET balance_sheet (quarterly, 2026-03-31) — Prepaid Assets: 58017000.00
VET income_statement (quarterly, 2026-03-31) — Pretax Income: -242331000.00
VET balance_sheet (quarterly, 2026-03-31) — Properties: 258217000.00
VET cash_flow (quarterly, 2026-03-31) — Purchase Of Business: -6035000.00
VET cash_flow (quarterly, 2026-03-31) — Purchase Of PPE: -134580000.00
VET balance_sheet (quarterly, 2026-03-31) — Receivables: 279074000.00
VET income_statement (quarterly, 2026-03-31) — Reconciled Cost Of Revenue: 201194000.00
VET income_statement (quarterly, 2026-03-31) — Reconciled Depreciation: 169267000.00
VET cash_flow (quarterly, 2026-03-31) — Repayment Of Debt: -16223000.00
VET cash_flow (quarterly, 2026-03-31) — Repurchase Of Capital Stock: -4692000.00
VET balance_sheet (quarterly, 2026-03-31) — Retained Earnings: -2142161000.00
VET income_statement (quarterly, 2026-03-31) — Salaries And Wages: 2451000.00
VET income_statement (quarterly, 2026-03-31) — Selling General And Administration: 22416000.00
VET balance_sheet (quarterly, 2026-03-31) — Share Issued: 152599504.00
VET cash_flow (quarterly, 2026-03-31) — Stock Based Compensation: 2451000.00
VET balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: 2044623000.00
VET balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: 2044623000.00
VET income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: -126940000.00
VET income_statement (quarterly, 2026-03-31) — Tax Provision: -101125000.00
VET income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.40
VET balance_sheet (quarterly, 2026-03-31) — Taxes Receivable: 10759000.00
VET balance_sheet (quarterly, 2026-03-31) — Total Assets: 5546526000.00
VET balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 3298956000.00
VET balance_sheet (quarterly, 2026-03-31) — Total Debt: 1303119000.00
VET balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: 2044623000.00
VET income_statement (quarterly, 2026-03-31) — Total Expenses: 417460000.00
VET balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 3501903000.00
VET balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 5061742000.00
VET balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 2736831000.00
VET balance_sheet (quarterly, 2026-03-31) — Total Tax Payable: 30131000.00
VET income_statement (quarterly, 2026-03-31) — Total Unusual Items: -317350000.00
VET income_statement (quarterly, 2026-03-31) — Total Unusual Items Excluding Goodwill: -317350000.00
VET balance_sheet (quarterly, 2026-03-31) — Working Capital: -280288000.00
VET.TO income_statement (annual, 2021-12-31) — Impairment Of Capital Assets: -1302619000.00
VET.TO cash_flow (annual, 2021-12-31) — Net Short Term Debt Issuance: -341259000.00
VET.TO income_statement (annual, 2021-12-31) — Restructuring And Mergern Acquisition: -17198000.00
VET.TO income_statement (annual, 2021-12-31) — Write Off: -1302619000.00
VET.TO income_statement (annual, 2022-12-31) — +Operating Expense: 728167000.00
VET.TO income_statement (annual, 2022-12-31) — +Total Revenue: 3721228000.00
VET.TO balance_sheet (annual, 2022-12-31) — Accounts Payable: 481444000.00
VET.TO balance_sheet (annual, 2022-12-31) — Accounts Receivable: 373651000.00
VET.TO balance_sheet (annual, 2022-12-31) — Accumulated Depreciation: -6572976000.00
VET.TO balance_sheet (annual, 2022-12-31) — Additional Paid In Capital: 35409000.00
VET.TO cash_flow (annual, 2022-12-31) — Asset Impairment Charge: -192094000.00
VET.TO income_statement (annual, 2022-12-31) — Basic Average Shares: 163489000.00
VET.TO income_statement (annual, 2022-12-31) — Basic EPS: 8.03
VET.TO cash_flow (annual, 2022-12-31) — Beginning Cash Position: 6028000.00
VET.TO cash_flow (annual, 2022-12-31) — Capital Expenditure: -551817000.00
VET.TO balance_sheet (annual, 2022-12-31) — Capital Lease Obligations: 51507000.00
VET.TO balance_sheet (annual, 2022-12-31) — Capital Stock: 4243794000.00
VET.TO balance_sheet (annual, 2022-12-31) — Cash And Cash Equivalents: 13836000.00
VET.TO balance_sheet (annual, 2022-12-31) — Cash Cash Equivalents And Short Term Investments: 13836000.00
VET.TO cash_flow (annual, 2022-12-31) — Cash Dividends Paid: -32711000.00
VET.TO balance_sheet (annual, 2022-12-31) — Cash Equivalents: 135000.00
VET.TO balance_sheet (annual, 2022-12-31) — Cash Financial: 13701000.00
VET.TO cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Financing Activities: -748369000.00
VET.TO cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Investing Activities: -1059292000.00
VET.TO cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Operating Activities: 1814220000.00
VET.TO cash_flow (annual, 2022-12-31) — Change In Working Capital: 216869000.00
VET.TO cash_flow (annual, 2022-12-31) — Changes In Cash: 6559000.00
VET.TO balance_sheet (annual, 2022-12-31) — Common Stock: 4243794000.00
VET.TO balance_sheet (annual, 2022-12-31) — Common Stock Equity: 3401058000.00
VET.TO cash_flow (annual, 2022-12-31) — Common Stock Payments: -71659000.00
VET.TO income_statement (annual, 2022-12-31) — Cost Of Revenue: 1127985000.00
VET.TO balance_sheet (annual, 2022-12-31) — Current Assets: 714446000.00
VET.TO balance_sheet (annual, 2022-12-31) — Current Liabilities: 892045000.00
VET.TO cash_flow (annual, 2022-12-31) — Deferred Income Tax: 288707000.00
VET.TO cash_flow (annual, 2022-12-31) — Deferred Tax: 288707000.00
VET.TO cash_flow (annual, 2022-12-31) — Depreciation Amortization Depletion: 577134000.00
VET.TO balance_sheet (annual, 2022-12-31) — Derivative Product Liabilities: 0.00
VET.TO income_statement (annual, 2022-12-31) — Diluted Average Shares: 168426000.00
VET.TO income_statement (annual, 2022-12-31) — Diluted EPS: 7.80
VET.TO income_statement (annual, 2022-12-31) — Diluted NI Availto Com Stockholders: 1313062000.00
VET.TO balance_sheet (annual, 2022-12-31) — Dividends Payable: 13058000.00
VET.TO income_statement (annual, 2022-12-31) — EBIT: 2133957000.00
VET.TO income_statement (annual, 2022-12-31) — EBITDA: 2711091000.00
VET.TO cash_flow (annual, 2022-12-31) — Effect Of Exchange Rate Changes: 1249000.00
VET.TO cash_flow (annual, 2022-12-31) — End Cash Position: 13836000.00
VET.TO balance_sheet (annual, 2022-12-31) — Financial Assets: 132598000.00
VET.TO cash_flow (annual, 2022-12-31) — Financing Cash Flow: -748369000.00
VET.TO balance_sheet (annual, 2022-12-31) — Finished Goods: 19657000.00
VET.TO cash_flow (annual, 2022-12-31) — Free Cash Flow: 1262403000.00
VET.TO cash_flow (annual, 2022-12-31) — Gain Loss On Investment Securities: -540801000.00
VET.TO cash_flow (annual, 2022-12-31) — Gain Loss On Sale Of Business: 0.00
VET.TO income_statement (annual, 2022-12-31) — Gain On Sale Of Ppe: 0.00
VET.TO income_statement (annual, 2022-12-31) — Gain On Sale Of Security: 65638000.00
VET.TO balance_sheet (annual, 2022-12-31) — Gains Losses Not Affecting Retained Earnings: 123505000.00
VET.TO income_statement (annual, 2022-12-31) — General And Administrative Expense: 102067000.00
VET.TO balance_sheet (annual, 2022-12-31) — Gross PPE: 12535091000.00
VET.TO income_statement (annual, 2022-12-31) — Gross Profit: 2593243000.00
VET.TO balance_sheet (annual, 2022-12-31) — Hedging Assets Current: 162843000.00
VET.TO cash_flow (annual, 2022-12-31) — Income Tax Paid Supplemental Data: 144814000.00
VET.TO balance_sheet (annual, 2022-12-31) — Income Tax Payable: 341698000.00
VET.TO income_statement (annual, 2022-12-31) — Interest Expense: 82858000.00
VET.TO income_statement (annual, 2022-12-31) — Interest Expense Non Operating: 82858000.00
VET.TO cash_flow (annual, 2022-12-31) — Interest Paid Supplemental Data: 75042000.00
VET.TO balance_sheet (annual, 2022-12-31) — Inventory: 19657000.00
VET.TO balance_sheet (annual, 2022-12-31) — Invested Capital: 4482409000.00
VET.TO cash_flow (annual, 2022-12-31) — Investing Cash Flow: -1059292000.00
VET.TO balance_sheet (annual, 2022-12-31) — Investmentin Financial Assets: 56366000.00
VET.TO balance_sheet (annual, 2022-12-31) — Investments And Advances: 56366000.00
VET.TO cash_flow (annual, 2022-12-31) — Issuance Of Debt: 499037000.00
VET.TO balance_sheet (annual, 2022-12-31) — Long Term Capital Lease Obligation: 51507000.00
VET.TO balance_sheet (annual, 2022-12-31) — Long Term Debt: 1081351000.00
VET.TO balance_sheet (annual, 2022-12-31) — Long Term Debt And Capital Lease Obligation: 1132858000.00
VET.TO cash_flow (annual, 2022-12-31) — Long Term Debt Issuance: 499037000.00
VET.TO cash_flow (annual, 2022-12-31) — Long Term Debt Payments: -1143036000.00
VET.TO balance_sheet (annual, 2022-12-31) — Long Term Provisions: 1087757000.00
VET.TO cash_flow (annual, 2022-12-31) — Net Business Purchase And Sale: -510309000.00
VET.TO cash_flow (annual, 2022-12-31) — Net Common Stock Issuance: -71659000.00
VET.TO balance_sheet (annual, 2022-12-31) — Net Debt: 1067515000.00
VET.TO cash_flow (annual, 2022-12-31) — Net Foreign Currency Exchange Gain Loss: 84464000.00
VET.TO income_statement (annual, 2022-12-31) — Net Income: 1313062000.00
VET.TO income_statement (annual, 2022-12-31) — Net Income Common Stockholders: 1313062000.00
VET.TO income_statement (annual, 2022-12-31) — Net Income Continuous Operations: 1313062000.00
VET.TO income_statement (annual, 2022-12-31) — Net Income From Continuing And Discontinued Operation: 1313062000.00
VET.TO income_statement (annual, 2022-12-31) — Net Income From Continuing Operation Net Minority Interest: 1313062000.00
VET.TO cash_flow (annual, 2022-12-31) — Net Income From Continuing Operations: 1313062000.00
VET.TO income_statement (annual, 2022-12-31) — Net Income Including Noncontrolling Interests: 1313062000.00
VET.TO income_statement (annual, 2022-12-31) — Net Interest Income: -82858000.00
VET.TO cash_flow (annual, 2022-12-31) — Net Investment Purchase And Sale: -23282000.00
VET.TO cash_flow (annual, 2022-12-31) — Net Issuance Payments Of Debt: -643999000.00
VET.TO cash_flow (annual, 2022-12-31) — Net Long Term Debt Issuance: -643999000.00
VET.TO income_statement (annual, 2022-12-31) — Net Non Operating Interest Income Expense: -82858000.00
VET.TO cash_flow (annual, 2022-12-31) — Net Other Investing Changes: 26116000.00
VET.TO balance_sheet (annual, 2022-12-31) — Net PPE: 5962115000.00
VET.TO cash_flow (annual, 2022-12-31) — Net PPE Purchase And Sale: -551817000.00
VET.TO balance_sheet (annual, 2022-12-31) — Net Tangible Assets: 3401058000.00
VET.TO balance_sheet (annual, 2022-12-31) — Non Current Deferred Assets: 125533000.00
VET.TO balance_sheet (annual, 2022-12-31) — Non Current Deferred Liabilities: 477340000.00
VET.TO balance_sheet (annual, 2022-12-31) — Non Current Deferred Taxes Assets: 125533000.00
VET.TO balance_sheet (annual, 2022-12-31) — Non Current Deferred Taxes Liabilities: 477340000.00
VET.TO income_statement (annual, 2022-12-31) — Normalized EBITDA: 2453359000.00
VET.TO income_statement (annual, 2022-12-31) — Normalized Income: 1148068454.89
VET.TO cash_flow (annual, 2022-12-31) — Operating Cash Flow: 1814220000.00
VET.TO cash_flow (annual, 2022-12-31) — Operating Gains Losses: -456337000.00
VET.TO income_statement (annual, 2022-12-31) — Operating Income: 1865076000.00
VET.TO income_statement (annual, 2022-12-31) — Operating Revenue: 3721228000.00
VET.TO balance_sheet (annual, 2022-12-31) — Ordinary Shares Number: 163226618.00
VET.TO balance_sheet (annual, 2022-12-31) — Other Current Liabilities: 55845000.00
VET.TO balance_sheet (annual, 2022-12-31) — Other Equity Adjustments: 123505000.00
VET.TO income_statement (annual, 2022-12-31) — Other Gand A: 57677000.00
VET.TO income_statement (annual, 2022-12-31) — Other Income Expense: 268881000.00
VET.TO cash_flow (annual, 2022-12-31) — Other Non Cash Items: 22489000.00
VET.TO income_statement (annual, 2022-12-31) — Other Non Operating Income Expenses: 11149000.00
VET.TO income_statement (annual, 2022-12-31) — Other Operating Expenses: 626100000.00
VET.TO balance_sheet (annual, 2022-12-31) — Other Properties: 12058520000.00
VET.TO balance_sheet (annual, 2022-12-31) — Payables: 836200000.00
VET.TO balance_sheet (annual, 2022-12-31) — Payables And Accrued Expenses: 836200000.00
VET.TO balance_sheet (annual, 2022-12-31) — Prepaid Assets: 144459000.00
VET.TO income_statement (annual, 2022-12-31) — Pretax Income: 2051099000.00
VET.TO balance_sheet (annual, 2022-12-31) — Properties: 476571000.00
VET.TO cash_flow (annual, 2022-12-31) — Purchase Of Business: -510309000.00
VET.TO cash_flow (annual, 2022-12-31) — Purchase Of Investment: -23282000.00
VET.TO cash_flow (annual, 2022-12-31) — Purchase Of PPE: -551817000.00
VET.TO balance_sheet (annual, 2022-12-31) — Receivables: 373651000.00
VET.TO income_statement (annual, 2022-12-31) — Reconciled Cost Of Revenue: 1127985000.00
VET.TO income_statement (annual, 2022-12-31) — Reconciled Depreciation: 577134000.00
VET.TO cash_flow (annual, 2022-12-31) — Repayment Of Debt: -1143036000.00
VET.TO cash_flow (annual, 2022-12-31) — Repurchase Of Capital Stock: -71659000.00
VET.TO income_statement (annual, 2022-12-31) — Restructuring And Mergern Acquisition: 0.00
VET.TO balance_sheet (annual, 2022-12-31) — Retained Earnings: -1001650000.00
VET.TO income_statement (annual, 2022-12-31) — Salaries And Wages: 44390000.00
VET.TO cash_flow (annual, 2022-12-31) — Sale Of Business: 0.00
VET.TO income_statement (annual, 2022-12-31) — Selling General And Administration: 102067000.00
VET.TO balance_sheet (annual, 2022-12-31) — Share Issued: 163226618.00
VET.TO income_statement (annual, 2022-12-31) — Special Income Charges: 192094000.00
VET.TO cash_flow (annual, 2022-12-31) — Stock Based Compensation: 44390000.00
VET.TO balance_sheet (annual, 2022-12-31) — Stockholders Equity: 3401058000.00
VET.TO balance_sheet (annual, 2022-12-31) — Tangible Book Value: 3401058000.00
VET.TO income_statement (annual, 2022-12-31) — Tax Effect Of Unusual Items: 92738454.89
VET.TO income_statement (annual, 2022-12-31) — Tax Provision: 738037000.00
VET.TO income_statement (annual, 2022-12-31) — Tax Rate For Calcs: 0.36
VET.TO balance_sheet (annual, 2022-12-31) — Total Assets: 6991058000.00
VET.TO balance_sheet (annual, 2022-12-31) — Total Capitalization: 4482409000.00
VET.TO balance_sheet (annual, 2022-12-31) — Total Debt: 1132858000.00
VET.TO balance_sheet (annual, 2022-12-31) — Total Equity Gross Minority Interest: 3401058000.00
VET.TO income_statement (annual, 2022-12-31) — Total Expenses: 1856152000.00
VET.TO balance_sheet (annual, 2022-12-31) — Total Liabilities Net Minority Interest: 3590000000.00
VET.TO balance_sheet (annual, 2022-12-31) — Total Non Current Assets: 6276612000.00
VET.TO balance_sheet (annual, 2022-12-31) — Total Non Current Liabilities Net Minority Interest: 2697955000.00
VET.TO balance_sheet (annual, 2022-12-31) — Total Tax Payable: 341698000.00
VET.TO income_statement (annual, 2022-12-31) — Total Unusual Items: 257732000.00
VET.TO income_statement (annual, 2022-12-31) — Total Unusual Items Excluding Goodwill: 257732000.00
VET.TO balance_sheet (annual, 2022-12-31) — Working Capital: -177599000.00
VET.TO income_statement (annual, 2022-12-31) — Write Off: -192094000.00
VET.TO income_statement (annual, 2023-12-31) — +Operating Expense: 803896000.00
VET.TO income_statement (annual, 2023-12-31) — +Total Revenue: 2199555000.00
VET.TO balance_sheet (annual, 2023-12-31) — Accounts Payable: 380370000.00
VET.TO balance_sheet (annual, 2023-12-31) — Accounts Receivable: 242926000.00
VET.TO balance_sheet (annual, 2023-12-31) — Accumulated Depreciation: -8317713000.00
VET.TO balance_sheet (annual, 2023-12-31) — Additional Paid In Capital: 43348000.00
VET.TO cash_flow (annual, 2023-12-31) — Asset Impairment Charge: 1016094000.00
VET.TO income_statement (annual, 2023-12-31) — Basic Average Shares: 163719000.00
VET.TO income_statement (annual, 2023-12-31) — Basic EPS: -1.45
VET.TO cash_flow (annual, 2023-12-31) — Beginning Cash Position: 13836000.00
VET.TO cash_flow (annual, 2023-12-31) — Capital Expenditure: -732472000.00
VET.TO balance_sheet (annual, 2023-12-31) — Capital Lease Obligations: 33001000.00
VET.TO balance_sheet (annual, 2023-12-31) — Capital Stock: 4142566000.00
VET.TO balance_sheet (annual, 2023-12-31) — Cash And Cash Equivalents: 141456000.00
VET.TO balance_sheet (annual, 2023-12-31) — Cash Cash Equivalents And Short Term Investments: 141456000.00
VET.TO cash_flow (annual, 2023-12-31) — Cash Dividends Paid: -62080000.00
VET.TO balance_sheet (annual, 2023-12-31) — Cash Equivalents: 661000.00
VET.TO balance_sheet (annual, 2023-12-31) — Cash Financial: 140795000.00
VET.TO cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Financing Activities: -320336000.00
VET.TO cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Investing Activities: -576435000.00
VET.TO cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Operating Activities: 1024528000.00
VET.TO cash_flow (annual, 2023-12-31) — Change In Working Capital: -61117000.00
VET.TO cash_flow (annual, 2023-12-31) — Changes In Cash: 127757000.00
VET.TO balance_sheet (annual, 2023-12-31) — Common Stock: 4142566000.00
VET.TO balance_sheet (annual, 2023-12-31) — Common Stock Equity: 3031648000.00
VET.TO cash_flow (annual, 2023-12-31) — Common Stock Payments: -94838000.00
VET.TO income_statement (annual, 2023-12-31) — Cost Of Revenue: 1081313000.00
VET.TO balance_sheet (annual, 2023-12-31) — Current Assets: 823514000.00
VET.TO balance_sheet (annual, 2023-12-31) — Current Liabilities: 696074000.00
VET.TO cash_flow (annual, 2023-12-31) — Deferred Income Tax: -190193000.00
VET.TO cash_flow (annual, 2023-12-31) — Deferred Tax: -190193000.00
VET.TO cash_flow (annual, 2023-12-31) — Depreciation Amortization Depletion: 712619000.00
VET.TO balance_sheet (annual, 2023-12-31) — Derivative Product Liabilities: 21050000.00
VET.TO income_statement (annual, 2023-12-31) — Diluted Average Shares: 163719000.00
VET.TO income_statement (annual, 2023-12-31) — Diluted EPS: -1.45
VET.TO income_statement (annual, 2023-12-31) — Diluted NI Availto Com Stockholders: -237587000.00
VET.TO balance_sheet (annual, 2023-12-31) — Dividends Payable: 16227000.00
VET.TO income_statement (annual, 2023-12-31) — EBIT: -193070000.00
VET.TO income_statement (annual, 2023-12-31) — EBITDA: 519549000.00
VET.TO cash_flow (annual, 2023-12-31) — Effect Of Exchange Rate Changes: -137000.00
VET.TO cash_flow (annual, 2023-12-31) — End Cash Position: 141456000.00
VET.TO balance_sheet (annual, 2023-12-31) — Financial Assets: 76107000.00
VET.TO cash_flow (annual, 2023-12-31) — Financing Cash Flow: -320336000.00
VET.TO balance_sheet (annual, 2023-12-31) — Finished Goods: 57333000.00
VET.TO cash_flow (annual, 2023-12-31) — Free Cash Flow: 292056000.00
VET.TO cash_flow (annual, 2023-12-31) — Gain Loss On Investment Securities: -179707000.00
VET.TO cash_flow (annual, 2023-12-31) — Gain Loss On Sale Of Business: 352367000.00
VET.TO income_statement (annual, 2023-12-31) — Gain On Sale Of Ppe: -352367000.00
VET.TO income_statement (annual, 2023-12-31) — Gain On Sale Of Security: 421978000.00
VET.TO balance_sheet (annual, 2023-12-31) — Gains Losses Not Affecting Retained Earnings: 109302000.00
VET.TO income_statement (annual, 2023-12-31) — General And Administrative Expense: 123472000.00
VET.TO balance_sheet (annual, 2023-12-31) — Gross PPE: 13398601000.00
VET.TO income_statement (annual, 2023-12-31) — Gross Profit: 1118242000.00
VET.TO balance_sheet (annual, 2023-12-31) — Hedging Assets Current: 313792000.00
VET.TO cash_flow (annual, 2023-12-31) — Income Tax Paid Supplemental Data: 306911000.00
VET.TO balance_sheet (annual, 2023-12-31) — Income Tax Payable: 298745000.00
VET.TO income_statement (annual, 2023-12-31) — Interest Expense: 85212000.00
VET.TO income_statement (annual, 2023-12-31) — Interest Expense Non Operating: 85212000.00
VET.TO cash_flow (annual, 2023-12-31) — Interest Paid Supplemental Data: 84471000.00
VET.TO balance_sheet (annual, 2023-12-31) — Inventory: 57333000.00
VET.TO balance_sheet (annual, 2023-12-31) — Invested Capital: 3945663000.00
VET.TO cash_flow (annual, 2023-12-31) — Investing Cash Flow: -576435000.00
VET.TO balance_sheet (annual, 2023-12-31) — Investmentin Financial Assets: 73261000.00
VET.TO balance_sheet (annual, 2023-12-31) — Investments And Advances: 73261000.00
VET.TO cash_flow (annual, 2023-12-31) — Issuance Of Debt: 0.00
VET.TO balance_sheet (annual, 2023-12-31) — Long Term Capital Lease Obligation: 33001000.00
VET.TO balance_sheet (annual, 2023-12-31) — Long Term Debt: 914015000.00
VET.TO balance_sheet (annual, 2023-12-31) — Long Term Debt And Capital Lease Obligation: 947016000.00
VET.TO cash_flow (annual, 2023-12-31) — Long Term Debt Issuance: 0.00
VET.TO cash_flow (annual, 2023-12-31) — Long Term Debt Payments: -163418000.00
VET.TO balance_sheet (annual, 2023-12-31) — Long Term Provisions: 1159063000.00
VET.TO cash_flow (annual, 2023-12-31) — Net Business Purchase And Sale: 54726000.00
VET.TO cash_flow (annual, 2023-12-31) — Net Common Stock Issuance: -94838000.00
VET.TO balance_sheet (annual, 2023-12-31) — Net Debt: 772559000.00
VET.TO cash_flow (annual, 2023-12-31) — Net Foreign Currency Exchange Gain Loss: -12438000.00
VET.TO income_statement (annual, 2023-12-31) — Net Income: -237587000.00
VET.TO income_statement (annual, 2023-12-31) — Net Income Common Stockholders: -237587000.00
VET.TO income_statement (annual, 2023-12-31) — Net Income Continuous Operations: -237587000.00
VET.TO income_statement (annual, 2023-12-31) — Net Income From Continuing And Discontinued Operation: -237587000.00
VET.TO income_statement (annual, 2023-12-31) — Net Income From Continuing Operation Net Minority Interest: -237587000.00
VET.TO cash_flow (annual, 2023-12-31) — Net Income From Continuing Operations: -237587000.00
VET.TO income_statement (annual, 2023-12-31) — Net Income Including Noncontrolling Interests: -237587000.00
VET.TO income_statement (annual, 2023-12-31) — Net Interest Income: -85212000.00
VET.TO cash_flow (annual, 2023-12-31) — Net Investment Purchase And Sale: -21603000.00
VET.TO cash_flow (annual, 2023-12-31) — Net Issuance Payments Of Debt: -163418000.00
VET.TO cash_flow (annual, 2023-12-31) — Net Long Term Debt Issuance: -163418000.00
VET.TO income_statement (annual, 2023-12-31) — Net Non Operating Interest Income Expense: -85212000.00
VET.TO cash_flow (annual, 2023-12-31) — Net Other Investing Changes: -19367000.00
VET.TO balance_sheet (annual, 2023-12-31) — Net PPE: 5080888000.00
VET.TO cash_flow (annual, 2023-12-31) — Net PPE Purchase And Sale: -535465000.00
VET.TO balance_sheet (annual, 2023-12-31) — Net Tangible Assets: 3031648000.00
VET.TO balance_sheet (annual, 2023-12-31) — Non Current Deferred Assets: 182051000.00
VET.TO balance_sheet (annual, 2023-12-31) — Non Current Deferred Liabilities: 380970000.00
VET.TO balance_sheet (annual, 2023-12-31) — Non Current Deferred Taxes Assets: 182051000.00
VET.TO balance_sheet (annual, 2023-12-31) — Non Current Deferred Taxes Liabilities: 380970000.00
VET.TO income_statement (annual, 2023-12-31) — Normalized EBITDA: 1026545000.00
VET.TO income_statement (annual, 2023-12-31) — Normalized Income: 195267653.38
VET.TO cash_flow (annual, 2023-12-31) — Operating Cash Flow: 1024528000.00
VET.TO cash_flow (annual, 2023-12-31) — Operating Gains Losses: 160222000.00
VET.TO income_statement (annual, 2023-12-31) — Operating Income: 314346000.00
VET.TO income_statement (annual, 2023-12-31) — Operating Revenue: 2199555000.00
VET.TO balance_sheet (annual, 2023-12-31) — Ordinary Shares Number: 162271071.00
VET.TO balance_sheet (annual, 2023-12-31) — Other Current Liabilities: 732000.00
VET.TO balance_sheet (annual, 2023-12-31) — Other Equity Adjustments: 109302000.00
VET.TO income_statement (annual, 2023-12-31) — Other Gand A: 80716000.00
VET.TO income_statement (annual, 2023-12-31) — Other Income Expense: -507416000.00
VET.TO cash_flow (annual, 2023-12-31) — Other Non Cash Items: -418266000.00
VET.TO income_statement (annual, 2023-12-31) — Other Non Operating Income Expenses: -420000.00
VET.TO income_statement (annual, 2023-12-31) — Other Operating Expenses: 680424000.00
VET.TO balance_sheet (annual, 2023-12-31) — Other Properties: 12966256000.00
VET.TO balance_sheet (annual, 2023-12-31) — Payables: 695342000.00
VET.TO balance_sheet (annual, 2023-12-31) — Payables And Accrued Expenses: 695342000.00
VET.TO balance_sheet (annual, 2023-12-31) — Prepaid Assets: 68007000.00
VET.TO income_statement (annual, 2023-12-31) — Pretax Income: -278282000.00
VET.TO balance_sheet (annual, 2023-12-31) — Properties: 432345000.00
VET.TO cash_flow (annual, 2023-12-31) — Purchase Of Business: -142281000.00
VET.TO cash_flow (annual, 2023-12-31) — Purchase Of Investment: -21603000.00
VET.TO cash_flow (annual, 2023-12-31) — Purchase Of PPE: -732472000.00
VET.TO balance_sheet (annual, 2023-12-31) — Receivables: 242926000.00
VET.TO income_statement (annual, 2023-12-31) — Reconciled Cost Of Revenue: 1081313000.00
VET.TO income_statement (annual, 2023-12-31) — Reconciled Depreciation: 712619000.00
VET.TO cash_flow (annual, 2023-12-31) — Repayment Of Debt: -163418000.00
VET.TO cash_flow (annual, 2023-12-31) — Repurchase Of Capital Stock: -94838000.00
VET.TO income_statement (annual, 2023-12-31) — Restructuring And Mergern Acquisition: -439487000.00
VET.TO balance_sheet (annual, 2023-12-31) — Retained Earnings: -1263568000.00
VET.TO income_statement (annual, 2023-12-31) — Salaries And Wages: 42756000.00
VET.TO cash_flow (annual, 2023-12-31) — Sale Of Business: 197007000.00
VET.TO cash_flow (annual, 2023-12-31) — Sale Of PPE: 197007000.00
VET.TO income_statement (annual, 2023-12-31) — Selling General And Administration: 123472000.00
VET.TO balance_sheet (annual, 2023-12-31) — Share Issued: 162271071.00
VET.TO income_statement (annual, 2023-12-31) — Special Income Charges: -928974000.00
VET.TO cash_flow (annual, 2023-12-31) — Stock Based Compensation: 42756000.00
VET.TO balance_sheet (annual, 2023-12-31) — Stockholders Equity: 3031648000.00
VET.TO balance_sheet (annual, 2023-12-31) — Tangible Book Value: 3031648000.00
VET.TO income_statement (annual, 2023-12-31) — Tax Effect Of Unusual Items: -74141346.62
VET.TO income_statement (annual, 2023-12-31) — Tax Provision: -40695000.00
VET.TO income_statement (annual, 2023-12-31) — Tax Rate For Calcs: 0.15
VET.TO balance_sheet (annual, 2023-12-31) — Total Assets: 6235821000.00
VET.TO balance_sheet (annual, 2023-12-31) — Total Capitalization: 3945663000.00
VET.TO balance_sheet (annual, 2023-12-31) — Total Debt: 947016000.00
VET.TO balance_sheet (annual, 2023-12-31) — Total Equity Gross Minority Interest: 3031648000.00
VET.TO income_statement (annual, 2023-12-31) — Total Expenses: 1885209000.00
VET.TO balance_sheet (annual, 2023-12-31) — Total Liabilities Net Minority Interest: 3204173000.00
VET.TO balance_sheet (annual, 2023-12-31) — Total Non Current Assets: 5412307000.00
VET.TO balance_sheet (annual, 2023-12-31) — Total Non Current Liabilities Net Minority Interest: 2508099000.00
VET.TO balance_sheet (annual, 2023-12-31) — Total Tax Payable: 298745000.00
VET.TO income_statement (annual, 2023-12-31) — Total Unusual Items: -506996000.00
VET.TO income_statement (annual, 2023-12-31) — Total Unusual Items Excluding Goodwill: -506996000.00
VET.TO balance_sheet (annual, 2023-12-31) — Working Capital: 127440000.00
VET.TO income_statement (annual, 2023-12-31) — Write Off: 1016094000.00
VET.TO cash_flow (quarterly, 2024-09-30) — Asset Impairment Charge: 0.00
VET.TO income_statement (quarterly, 2024-09-30) — Basic Average Shares: 156624000.00
VET.TO income_statement (quarterly, 2024-09-30) — Basic EPS: 0.33
VET.TO cash_flow (quarterly, 2024-09-30) — Capital Expenditure Reported: -121269000.00
VET.TO cash_flow (quarterly, 2024-09-30) — Common Stock Dividend Paid: -18981000.00
VET.TO income_statement (quarterly, 2024-09-30) — Diluted Average Shares: 157502000.00
VET.TO income_statement (quarterly, 2024-09-30) — Diluted EPS: 0.33
VET.TO cash_flow (quarterly, 2024-09-30) — Gain Loss On Sale Of PPE: 0.00
VET.TO income_statement (quarterly, 2024-09-30) — Gain On Sale Of Ppe: 0.00
VET.TO cash_flow (quarterly, 2024-09-30) — Net Short Term Debt Issuance: 0.00
VET.TO income_statement (quarterly, 2024-09-30) — Restructuring And Mergern Acquisition: 0.00
VET.TO cash_flow (quarterly, 2024-09-30) — Sale Of PPE: 0.00
VET.TO cash_flow (quarterly, 2024-09-30) — Short Term Debt Issuance: 0.00
VET.TO income_statement (quarterly, 2024-09-30) — Special Income Charges: 0.00
VET.TO income_statement (annual, 2024-12-31) — +Operating Expense: 702539000.00
VET.TO income_statement (annual, 2024-12-31) — +Total Revenue: 1639336000.00
VET.TO balance_sheet (annual, 2024-12-31) — Accounts Payable: 425410000.00
VET.TO balance_sheet (annual, 2024-12-31) — Accounts Receivable: 298493000.00
VET.TO balance_sheet (annual, 2024-12-31) — Accumulated Depreciation: -8978087000.00
VET.TO balance_sheet (quarterly, 2024-12-31) — Accumulated Depreciation: -8978087000.00
VET.TO balance_sheet (annual, 2024-12-31) — Additional Paid In Capital: 45225000.00
VET.TO cash_flow (annual, 2024-12-31) — Asset Impairment Charge: 0.00
VET.TO balance_sheet (annual, 2024-12-31) — Available For Sale Securities: 78862000.00
VET.TO balance_sheet (quarterly, 2024-12-31) — Available For Sale Securities: 78862000.00
VET.TO income_statement (annual, 2024-12-31) — Basic Average Shares: 158068000.00
VET.TO income_statement (annual, 2024-12-31) — Basic EPS: -0.30
VET.TO cash_flow (annual, 2024-12-31) — Beginning Cash Position: 141456000.00
VET.TO cash_flow (annual, 2024-12-31) — Capital Expenditure: -622980000.00
VET.TO cash_flow (quarterly, 2024-12-31) — Capital Expenditure: -205916000.00
VET.TO balance_sheet (annual, 2024-12-31) — Capital Lease Obligations: 54991000.00
VET.TO balance_sheet (annual, 2024-12-31) — Capital Stock: 3918898000.00
VET.TO balance_sheet (annual, 2024-12-31) — Cash And Cash Equivalents: 131730000.00
VET.TO balance_sheet (annual, 2024-12-31) — Cash Cash Equivalents And Short Term Investments: 131730000.00
VET.TO cash_flow (annual, 2024-12-31) — Cash Dividends Paid: -73033000.00
VET.TO balance_sheet (annual, 2024-12-31) — Cash Equivalents: 6792000.00
VET.TO balance_sheet (annual, 2024-12-31) — Cash Financial: 124938000.00
VET.TO cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Financing Activities: -344084000.00
VET.TO cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Investing Activities: -634868000.00
VET.TO cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Operating Activities: 967751000.00
VET.TO cash_flow (annual, 2024-12-31) — Change In Working Capital: -182698000.00
VET.TO cash_flow (annual, 2024-12-31) — Changes In Cash: -11201000.00
VET.TO balance_sheet (annual, 2024-12-31) — Common Stock: 3918898000.00
VET.TO balance_sheet (annual, 2024-12-31) — Common Stock Equity: 2810989000.00
VET.TO cash_flow (annual, 2024-12-31) — Common Stock Payments: -140707000.00
VET.TO income_statement (annual, 2024-12-31) — Cost Of Revenue: 749741000.00
VET.TO balance_sheet (annual, 2024-12-31) — Current Assets: 582326000.00
VET.TO balance_sheet (annual, 2024-12-31) — Current Liabilities: 664178000.00
VET.TO cash_flow (annual, 2024-12-31) — Deferred Income Tax: -37991000.00
VET.TO cash_flow (annual, 2024-12-31) — Deferred Tax: -37991000.00
VET.TO cash_flow (annual, 2024-12-31) — Depreciation Amortization Depletion: 683240000.00
VET.TO balance_sheet (annual, 2024-12-31) — Derivative Product Liabilities: 86036000.00
VET.TO income_statement (annual, 2024-12-31) — Diluted Average Shares: 158068000.00
VET.TO income_statement (annual, 2024-12-31) — Diluted EPS: -0.30
VET.TO income_statement (annual, 2024-12-31) — Diluted NI Availto Com Stockholders: -46739000.00
VET.TO balance_sheet (annual, 2024-12-31) — Dividends Payable: 18521000.00
VET.TO balance_sheet (quarterly, 2024-12-31) — Dividends Payable: 18521000.00
VET.TO income_statement (annual, 2024-12-31) — EBIT: 14687000.00
VET.TO income_statement (annual, 2024-12-31) — EBITDA: 697927000.00
VET.TO cash_flow (annual, 2024-12-31) — Effect Of Exchange Rate Changes: 1475000.00
VET.TO cash_flow (annual, 2024-12-31) — End Cash Position: 131730000.00
VET.TO balance_sheet (annual, 2024-12-31) — Financial Assets: 13927000.00
VET.TO cash_flow (annual, 2024-12-31) — Financing Cash Flow: -344084000.00
VET.TO balance_sheet (annual, 2024-12-31) — Finished Goods: 40694000.00
VET.TO cash_flow (annual, 2024-12-31) — Free Cash Flow: 344771000.00
VET.TO cash_flow (annual, 2024-12-31) — Gain Loss On Investment Securities: 452858000.00
VET.TO cash_flow (annual, 2024-12-31) — Gain Loss On Sale Of Business: 0.00
VET.TO income_statement (annual, 2024-12-31) — Gain On Sale Of Ppe: 0.00
VET.TO income_statement (quarterly, 2024-12-31) — Gain On Sale Of Ppe: 0.00
VET.TO income_statement (annual, 2024-12-31) — Gain On Sale Of Security: -159268000.00
VET.TO balance_sheet (annual, 2024-12-31) — Gains Losses Not Affecting Retained Earnings: 135847000.00
VET.TO income_statement (annual, 2024-12-31) — General And Administrative Expense: 103940000.00
VET.TO balance_sheet (annual, 2024-12-31) — Gross PPE: 14220834000.00
VET.TO income_statement (annual, 2024-12-31) — Gross Profit: 889595000.00
VET.TO balance_sheet (annual, 2024-12-31) — Hedging Assets Current: 40312000.00
VET.TO cash_flow (annual, 2024-12-31) — Income Tax Paid Supplemental Data: 263048000.00
VET.TO cash_flow (quarterly, 2024-12-31) — Income Tax Paid Supplemental Data: 47960000.00
VET.TO balance_sheet (annual, 2024-12-31) — Income Tax Payable: 113715000.00
VET.TO income_statement (annual, 2024-12-31) — Interest Expense: 84606000.00
VET.TO income_statement (annual, 2024-12-31) — Interest Expense Non Operating: 84606000.00
VET.TO cash_flow (annual, 2024-12-31) — Interest Paid Supplemental Data: 85649000.00
VET.TO balance_sheet (annual, 2024-12-31) — Inventory: 40694000.00
VET.TO balance_sheet (annual, 2024-12-31) — Invested Capital: 3774445000.00
VET.TO cash_flow (annual, 2024-12-31) — Investing Cash Flow: -634868000.00
VET.TO balance_sheet (annual, 2024-12-31) — Investmentin Financial Assets: 78862000.00
VET.TO balance_sheet (annual, 2024-12-31) — Investments And Advances: 78862000.00
VET.TO cash_flow (annual, 2024-12-31) — Issuance Of Debt: 0.00
VET.TO balance_sheet (annual, 2024-12-31) — Long Term Capital Lease Obligation: 54991000.00
VET.TO balance_sheet (annual, 2024-12-31) — Long Term Debt: 963456000.00
VET.TO balance_sheet (annual, 2024-12-31) — Long Term Debt And Capital Lease Obligation: 1018447000.00
VET.TO cash_flow (annual, 2024-12-31) — Long Term Debt Issuance: 0.00
VET.TO cash_flow (annual, 2024-12-31) — Long Term Debt Payments: -133100000.00
VET.TO balance_sheet (annual, 2024-12-31) — Long Term Provisions: 1171130000.00
VET.TO cash_flow (annual, 2024-12-31) — Net Business Purchase And Sale: -12728000.00
VET.TO cash_flow (annual, 2024-12-31) — Net Common Stock Issuance: -140707000.00
VET.TO balance_sheet (annual, 2024-12-31) — Net Debt: 831726000.00
VET.TO cash_flow (annual, 2024-12-31) — Net Foreign Currency Exchange Gain Loss: 58471000.00
VET.TO income_statement (annual, 2024-12-31) — Net Income: -46739000.00
VET.TO income_statement (annual, 2024-12-31) — Net Income Common Stockholders: -46739000.00
VET.TO income_statement (annual, 2024-12-31) — Net Income Continuous Operations: -96169000.00
VET.TO income_statement (annual, 2024-12-31) — Net Income Discontinuous Operations: 49430000.00
VET.TO income_statement (annual, 2024-12-31) — Net Income From Continuing And Discontinued Operation: -46739000.00
VET.TO income_statement (annual, 2024-12-31) — Net Income From Continuing Operation Net Minority Interest: -96169000.00
VET.TO cash_flow (annual, 2024-12-31) — Net Income From Continuing Operations: -46739000.00
VET.TO income_statement (annual, 2024-12-31) — Net Income Including Noncontrolling Interests: -46739000.00
VET.TO income_statement (annual, 2024-12-31) — Net Interest Income: -84606000.00
VET.TO cash_flow (annual, 2024-12-31) — Net Investment Purchase And Sale: -9373000.00
VET.TO cash_flow (quarterly, 2024-12-31) — Net Investment Purchase And Sale: 0.00
VET.TO cash_flow (annual, 2024-12-31) — Net Issuance Payments Of Debt: -133100000.00
VET.TO cash_flow (annual, 2024-12-31) — Net Long Term Debt Issuance: -133100000.00
VET.TO income_statement (annual, 2024-12-31) — Net Non Operating Interest Income Expense: -84606000.00
VET.TO cash_flow (annual, 2024-12-31) — Net Other Financing Charges: 2756000.00
VET.TO cash_flow (annual, 2024-12-31) — Net Other Investing Changes: 10213000.00
VET.TO balance_sheet (annual, 2024-12-31) — Net PPE: 5242747000.00
VET.TO cash_flow (annual, 2024-12-31) — Net PPE Purchase And Sale: -622980000.00
VET.TO cash_flow (annual, 2024-12-31) — Net Short Term Debt Issuance: 0.00
VET.TO balance_sheet (annual, 2024-12-31) — Net Tangible Assets: 2810989000.00
VET.TO balance_sheet (annual, 2024-12-31) — Non Current Deferred Assets: 197714000.00
VET.TO balance_sheet (annual, 2024-12-31) — Non Current Deferred Liabilities: 364796000.00
VET.TO balance_sheet (annual, 2024-12-31) — Non Current Deferred Taxes Assets: 197714000.00
VET.TO balance_sheet (annual, 2024-12-31) — Non Current Deferred Taxes Liabilities: 364796000.00
VET.TO income_statement (annual, 2024-12-31) — Normalized EBITDA: 857195000.00
VET.TO income_statement (annual, 2024-12-31) — Normalized Income: 39208800.00
VET.TO cash_flow (annual, 2024-12-31) — Operating Cash Flow: 967751000.00
VET.TO cash_flow (annual, 2024-12-31) — Operating Gains Losses: 511329000.00
VET.TO income_statement (annual, 2024-12-31) — Operating Income: 187056000.00
VET.TO income_statement (annual, 2024-12-31) — Operating Revenue: 1639336000.00
VET.TO balance_sheet (annual, 2024-12-31) — Ordinary Shares Number: 154344353.00
VET.TO balance_sheet (annual, 2024-12-31) — Other Current Liabilities: 106532000.00
VET.TO balance_sheet (annual, 2024-12-31) — Other Equity Adjustments: 135847000.00
VET.TO income_statement (annual, 2024-12-31) — Other Gand A: 74010000.00
VET.TO income_statement (annual, 2024-12-31) — Other Income Expense: -172369000.00
VET.TO cash_flow (annual, 2024-12-31) — Other Non Cash Items: 25041000.00
VET.TO income_statement (annual, 2024-12-31) — Other Non Operating Income Expenses: -13101000.00
VET.TO income_statement (annual, 2024-12-31) — Other Operating Expenses: 598599000.00
VET.TO balance_sheet (annual, 2024-12-31) — Other Properties: 13760503000.00
VET.TO balance_sheet (quarterly, 2024-12-31) — Other Properties: 13760503000.00
VET.TO balance_sheet (annual, 2024-12-31) — Payables: 557646000.00
VET.TO balance_sheet (annual, 2024-12-31) — Payables And Accrued Expenses: 557646000.00
VET.TO balance_sheet (annual, 2024-12-31) — Prepaid Assets: 71097000.00
VET.TO income_statement (annual, 2024-12-31) — Pretax Income: -69919000.00
VET.TO balance_sheet (annual, 2024-12-31) — Properties: 460331000.00
VET.TO cash_flow (annual, 2024-12-31) — Purchase Of Business: -12728000.00
VET.TO cash_flow (annual, 2024-12-31) — Purchase Of Investment: -9373000.00
VET.TO cash_flow (quarterly, 2024-12-31) — Purchase Of Investment: 0.00
VET.TO cash_flow (annual, 2024-12-31) — Purchase Of PPE: -622980000.00
VET.TO balance_sheet (annual, 2024-12-31) — Receivables: 298493000.00
VET.TO income_statement (annual, 2024-12-31) — Reconciled Cost Of Revenue: 749741000.00
VET.TO income_statement (annual, 2024-12-31) — Reconciled Depreciation: 683240000.00
VET.TO cash_flow (annual, 2024-12-31) — Repayment Of Debt: -133100000.00
VET.TO cash_flow (annual, 2024-12-31) — Repurchase Of Capital Stock: -140707000.00
VET.TO income_statement (annual, 2024-12-31) — Restructuring And Mergern Acquisition: 0.00
VET.TO income_statement (quarterly, 2024-12-31) — Restructuring And Mergern Acquisition: 0.00
VET.TO balance_sheet (annual, 2024-12-31) — Retained Earnings: -1288981000.00
VET.TO income_statement (annual, 2024-12-31) — Salaries And Wages: 29930000.00
VET.TO cash_flow (annual, 2024-12-31) — Sale Of Business: 0.00
VET.TO cash_flow (annual, 2024-12-31) — Sale Of Investment: 0.00
VET.TO cash_flow (annual, 2024-12-31) — Sale Of PPE: 0.00
VET.TO cash_flow (quarterly, 2024-12-31) — Sale Of PPE: 0.00
VET.TO income_statement (annual, 2024-12-31) — Selling General And Administration: 103940000.00
VET.TO balance_sheet (annual, 2024-12-31) — Share Issued: 154344353.00
VET.TO income_statement (annual, 2024-12-31) — Special Income Charges: 0.00
VET.TO income_statement (quarterly, 2024-12-31) — Special Income Charges: 0.00
VET.TO cash_flow (annual, 2024-12-31) — Stock Based Compensation: 15569000.00
VET.TO balance_sheet (annual, 2024-12-31) — Stockholders Equity: 2810989000.00
VET.TO balance_sheet (annual, 2024-12-31) — Tangible Book Value: 2810989000.00
VET.TO income_statement (annual, 2024-12-31) — Tax Effect Of Unusual Items: -23890200.00
VET.TO income_statement (annual, 2024-12-31) — Tax Provision: 26250000.00
VET.TO income_statement (annual, 2024-12-31) — Tax Rate For Calcs: 0.15
VET.TO balance_sheet (annual, 2024-12-31) — Taxes Receivable: 0.00
VET.TO balance_sheet (annual, 2024-12-31) — Total Assets: 6115576000.00
VET.TO balance_sheet (annual, 2024-12-31) — Total Capitalization: 3774445000.00
VET.TO balance_sheet (annual, 2024-12-31) — Total Debt: 1018447000.00
VET.TO balance_sheet (annual, 2024-12-31) — Total Equity Gross Minority Interest: 2810989000.00
VET.TO income_statement (annual, 2024-12-31) — Total Expenses: 1452280000.00
VET.TO balance_sheet (annual, 2024-12-31) — Total Liabilities Net Minority Interest: 3304587000.00
VET.TO balance_sheet (annual, 2024-12-31) — Total Non Current Assets: 5533250000.00
VET.TO balance_sheet (annual, 2024-12-31) — Total Non Current Liabilities Net Minority Interest: 2640409000.00
VET.TO balance_sheet (annual, 2024-12-31) — Total Tax Payable: 113715000.00
VET.TO income_statement (annual, 2024-12-31) — Total Unusual Items: -159268000.00
VET.TO income_statement (annual, 2024-12-31) — Total Unusual Items Excluding Goodwill: -159268000.00
VET.TO balance_sheet (annual, 2024-12-31) — Working Capital: -81852000.00
VET.TO income_statement (quarterly, 2025-03-31) — +Operating Expense: 193480000.00
VET.TO income_statement (quarterly, 2025-03-31) — +Total Revenue: 484968000.00
VET.TO balance_sheet (quarterly, 2025-03-31) — Accounts Payable: 544377000.00
VET.TO balance_sheet (quarterly, 2025-03-31) — Accounts Receivable: 305955000.00
VET.TO balance_sheet (quarterly, 2025-03-31) — Additional Paid In Capital: 51156000.00
VET.TO income_statement (quarterly, 2025-03-31) — Basic Average Shares: 154173000.00
VET.TO income_statement (quarterly, 2025-03-31) — Basic EPS: 0.10
VET.TO cash_flow (quarterly, 2025-03-31) — Beginning Cash Position: 131730000.00
VET.TO cash_flow (quarterly, 2025-03-31) — Capital Expenditure: -182119000.00
VET.TO balance_sheet (quarterly, 2025-03-31) — Capital Lease Obligations: 56835000.00
VET.TO balance_sheet (quarterly, 2025-03-31) — Capital Stock: 3899688000.00
VET.TO balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 23528000.00
VET.TO balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 23528000.00
VET.TO cash_flow (quarterly, 2025-03-31) — Cash Dividends Paid: -18521000.00
VET.TO balance_sheet (quarterly, 2025-03-31) — Cash Equivalents: 5599000.00
VET.TO balance_sheet (quarterly, 2025-03-31) — Cash Financial: 17929000.00
VET.TO cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Financing Activities: 865986000.00
VET.TO cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Investing Activities: -1255746000.00
VET.TO cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Operating Activities: 280384000.00
VET.TO cash_flow (quarterly, 2025-03-31) — Change In Working Capital: 33702000.00
VET.TO cash_flow (quarterly, 2025-03-31) — Changes In Cash: -109376000.00
VET.TO balance_sheet (quarterly, 2025-03-31) — Common Stock: 3899688000.00
VET.TO cash_flow (quarterly, 2025-03-31) — Common Stock Dividend Paid: -18521000.00
VET.TO balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: 2881288000.00
VET.TO cash_flow (quarterly, 2025-03-31) — Common Stock Payments: -16576000.00
VET.TO income_statement (quarterly, 2025-03-31) — Cost Of Revenue: 194648000.00
VET.TO balance_sheet (quarterly, 2025-03-31) — Current Assets: 509726000.00
VET.TO balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 718144000.00
VET.TO cash_flow (quarterly, 2025-03-31) — Deferred Income Tax: -9016000.00
VET.TO cash_flow (quarterly, 2025-03-31) — Deferred Tax: -9016000.00
VET.TO cash_flow (quarterly, 2025-03-31) — Depreciation Amortization Depletion: 176388000.00
VET.TO balance_sheet (quarterly, 2025-03-31) — Derivative Product Liabilities: 81835000.00
VET.TO income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 155609000.00
VET.TO income_statement (quarterly, 2025-03-31) — Diluted EPS: 0.10
VET.TO income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: 14953000.00
VET.TO balance_sheet (quarterly, 2025-03-31) — Dividends Payable: 20043000.00
VET.TO income_statement (quarterly, 2025-03-31) — EBIT: 45982000.00
VET.TO income_statement (quarterly, 2025-03-31) — EBITDA: 222370000.00
VET.TO cash_flow (quarterly, 2025-03-31) — Effect Of Exchange Rate Changes: 1174000.00
VET.TO cash_flow (quarterly, 2025-03-31) — End Cash Position: 23528000.00